Shilpa Medicare530549Pharmaceuticals
Viewer asked about entering Shilpa Medicare after a 2.7% decline; analyst said wait for the fall to stabilize before buying
By ScoutQuest · · 1 min read
- Day's decline
- 2.7 percent
- Weekly RSI peak
- 93 to 95
- Support zone
- 900 to 915
Heard on business television between 10:39:50 - 10:42:50 IST.
- Stock fell 2.7% on the day, following a strong prior run where weekly RSI reached about 93-95.
- Analyst remains structurally constructive but advises against buying now since the fall has not stemmed, being in its second week of decline.
- Immediate support seen near 900-915 levels; if it holds there and consolidates, could become a buy again.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Shilpa Medicare
Shilpa Medicare gained 2% after one of its plants received a USFDA approval or acceptance letter for a key drug
22 Oct 2026
Shilpa Medicare rose about 4.5% after its partner Unicycive Therapeutics received USFDA acceptance of a resubmitted NDA application for a chronic kidney disease drug
22 Oct 2026
Nimesh flagged possible buying by a large global sovereign fund in Shilpa Medicare at current levels
14 Oct 2026
Source: Live TV News Channel · 15 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.